Regulus Therapeutics Inc
RGLS8.160USD
0.000
Close 12/26, 16:00（ET）Quotes delayed by 15 min
540.87MMarket Cap
LossP/E TTM
More Details of Regulus Therapeutics Inc Company
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
Regulus Therapeutics Inc Info
Ticker SymbolRGLS
Company nameRegulus Therapeutics Inc
IPO dateOct 04, 2012
CEOMr. Joseph P. (Jay) Hagan
Number of employees34
Security typeOrdinary Share
Fiscal year-endOct 04
Address4224 Campus Point Court
CitySAN DIEGO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92121
Phone18582026300
Websitehttps://www.regulusrx.com/
Ticker SymbolRGLS
IPO dateOct 04, 2012
CEOMr. Joseph P. (Jay) Hagan
Company Executives of Regulus Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Crispina Calsada, CPA
Ms. Crispina Calsada, CPA
Chief Financial Officer
Chief Financial Officer
56.73K
+24.74%
Mr. Christopher Ray Aker, J.D.
Mr. Christopher Ray Aker, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
50.55K
+402.65%
Mr. John Mckenna
Mr. John Mckenna
President, Director
President, Director
--
--
Mr. Eduard Marti
Mr. Eduard Marti
Director
Director
--
--
Ms. Rekha Garg
Ms. Rekha Garg
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Crispina Calsada, CPA
Ms. Crispina Calsada, CPA
Chief Financial Officer
Chief Financial Officer
56.73K
+24.74%
Mr. Christopher Ray Aker, J.D.
Mr. Christopher Ray Aker, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
50.55K
+402.65%
Mr. John Mckenna
Mr. John Mckenna
President, Director
President, Director
--
--
Mr. Eduard Marti
Mr. Eduard Marti
Director
Director
--
--
Ms. Rekha Garg
Ms. Rekha Garg
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Jul 3
Updated: Thu, Jul 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Federated Hermes Global Investment Management Corp.
22.85%
New Enterprise Associates (NEA)
9.34%
Octagon Capital Advisors LP
6.70%
The Vanguard Group, Inc.
5.71%
BlackRock Institutional Trust Company, N.A.
5.53%
Other
49.87%
Shareholders
Shareholders
Proportion
Federated Hermes Global Investment Management Corp.
22.85%
New Enterprise Associates (NEA)
9.34%
Octagon Capital Advisors LP
6.70%
The Vanguard Group, Inc.
5.71%
BlackRock Institutional Trust Company, N.A.
5.53%
Other
49.87%
Shareholder Types
Shareholders
Proportion
Individual Investor
0.80%
Investment Advisor
0.08%
Bank and Trust
0.06%
Other
99.07%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1
--
0.00%
-90.00
2025Q1
151
57.15M
82.75%
-7.04M
2024Q4
137
55.74M
85.10%
-6.54M
2024Q3
128
58.95M
90.05%
-6.89M
2024Q2
113
63.43M
96.89%
+3.08M
2024Q1
85
60.55M
95.51%
+47.86M
2023Q4
70
12.67M
62.78%
-270.56K
2023Q3
77
12.73M
68.68%
-335.94K
2023Q2
80
12.00M
64.97%
-983.27K
2023Q1
89
9.82M
61.73%
-1.56M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
No Data
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 28, 2022
Merger
10→1
Jun 28, 2022
Merger
10→1
Jun 28, 2022
Merger
10→1
Jun 28, 2022
Merger
10→1
Date
Type
Ratio
Jun 28, 2022
Merger
10→1
Jun 28, 2022
Merger
10→1
Jun 28, 2022
Merger
10→1
Jun 28, 2022
Merger
10→1
FAQs
Who are the top five shareholders of Regulus Therapeutics Inc?
The top five shareholders of Regulus Therapeutics Inc are:
What are the top three shareholder types of Regulus Therapeutics Inc?
The top three shareholder types of Regulus Therapeutics Inc are:
Federated Hermes Global Investment Management Corp.
New Enterprise Associates (NEA)
Octagon Capital Advisors LP
Federated Hermes Global Investment Management Corp.
New Enterprise Associates (NEA)
Octagon Capital Advisors LP
How many institutions hold shares of Regulus Therapeutics Inc (RGLS)?
As of 2025Q2, 1 institutions hold shares of Regulus Therapeutics Inc, with a combined market value of approximately --, accounting for --% of the total shares. Compared to 2025Q1, institutional shareholding has increased by -82.75%.
What is the biggest source of revenue for Regulus Therapeutics Inc?
In FY2021, the -- business generated the highest revenue for Regulus Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
